BioSpace News Archive

With the COVID-19 global pandemic spreading across the country, a Florida firm has pioneered a new way for doctors to securely share all patient records electronically with their staff now working from home.

As a leading national digital health and primary care organization, One Medical announced it is expanding its COVID-19 testing services to the general public.

To enhance COVID-19 tracking and trending, Biobot Analytics is applying its technology to analyze biological data from sewers to help identify the spread of SARS-CoV-2, the virus causing COVID-19.

Allen Technologies-a Sentrics Company released this week a rapid deployment wireless nurse call solution specifically for hospitals setting up popup, mobile and temporary facilities for COVID-19 and non-COVID patients.

Medical Devices & Diagnostics (MD&D) companies know they are being impacted by the current pandemic and are seeking independent research to quantify how much their markets will decline or increase, how long the recovery will take, and what factors will determine that recovery.

bioLytical Laboratories Inc., a world leader in rapid diagnostic tests for infectious diseases, is pleased to announce that its CEO, Livleen Veslemes, was recognized as the Change Maker of the Year in the BCBusiness Women of the Year Awards.

electroCore, Inc. announced that England’s National Health Service has exercised its option to extend the Innovation and Technology Payment Program for the use of gammaCore in the treatment of cluster headache in adults.

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, at 10:40 AM EST.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate results for the fourth quarter ended December 31, 2019.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy